Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1

Interventions

tislelizumab 12Capecitabine 8apatinib 5Surgical Procedures, Operative 5Carboplatin 5Oxaliplatin 4Drug Therapy 4Cisplatin 4Radiation 3Paclitaxel 3Immunotherapy 3Bevacizumab 3toripalimab 2anlotinib 2Standard of Care 2Radiotherapy 2Methods 2Melphalan 2Low-Level Light Therapy 2Letrozole 2Interleukin-2 2Injections 2Cryotherapy 2130-nm albumin-bound paclitaxel 2zanubrutinib 1trastuzumab deruxtecan 1sintilimab 1pyrotinib 1pertuzumab 1obinutuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × OTHER_GOV × Alendronate × Clear all
NCT07245381 2025-11-24

Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing Chemoradiation

Sheba Medical Center

Phase 1/2 Not yet recruiting
65 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡